Cargando…

The Risk of Virologic Failure Decreases with Duration of HIV Suppression, at Greater than 50% Adherence to Antiretroviral Therapy

BACKGROUND: We hypothesized that the percent adherence to antiretroviral therapy necessary to maintain HIV suppression would decrease with longer duration of viral suppression. METHODOLOGY: Eligible participants were identified from the REACH cohort of marginally housed HIV infected adults in San Fr...

Descripción completa

Detalles Bibliográficos
Autores principales: Rosenblum, Michael, Deeks, Steven G., van der Laan, Mark, Bangsberg, David R.
Formato: Texto
Lenguaje:English
Publicado: Public Library of Science 2009
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2747009/
https://www.ncbi.nlm.nih.gov/pubmed/19787058
http://dx.doi.org/10.1371/journal.pone.0007196
_version_ 1782172068308058112
author Rosenblum, Michael
Deeks, Steven G.
van der Laan, Mark
Bangsberg, David R.
author_facet Rosenblum, Michael
Deeks, Steven G.
van der Laan, Mark
Bangsberg, David R.
author_sort Rosenblum, Michael
collection PubMed
description BACKGROUND: We hypothesized that the percent adherence to antiretroviral therapy necessary to maintain HIV suppression would decrease with longer duration of viral suppression. METHODOLOGY: Eligible participants were identified from the REACH cohort of marginally housed HIV infected adults in San Francisco. Adherence to antiretroviral therapy was measured through pill counts obtained at unannounced visits by research staff to each participant's usual place of residence. Marginal structural models and targeted maximum likelihood estimation methodologies were used to determine the effect of adherence to antiretroviral therapy on the probability of virologic failure during early and late viral suppression. PRINCIPAL FINDINGS: A total of 221 subjects were studied (median age 44.1 years; median CD4+ T cell nadir 206 cells/mm(3)). Most subjects were taking the following types of antiretroviral regimens: non-nucleoside reverse transcriptase inhibitor based (37%), ritonavir boosted protease inhibitor based (28%), or unboosted protease inhibitor based (25%). Comparing the probability of failure just after achieving suppression vs. after 12 consecutive months of suppression, there was a statistically significant decrease in the probability of virologic failure for each range of adherence proportions we considered, as long as adherence was greater than 50%. The estimated risk difference, comparing the probability of virologic failure after 1 month vs. after 12 months of continuous viral suppression was 0.47 (95% CI 0.23–0.63) at 50–74% adherence, 0.29 (CI 0.03–0.50) at 75–89% adherence, and 0.36 (CI 0.23–0.48) at 90–100% adherence. CONCLUSIONS: The risk of virologic failure for adherence greater than 50% declines with longer duration of continuous suppression. While high adherence is required to maximize the probability of durable viral suppression, the range of adherence capable of sustaining viral suppression is wider after prolonged periods of viral suppression.
format Text
id pubmed-2747009
institution National Center for Biotechnology Information
language English
publishDate 2009
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-27470092009-09-29 The Risk of Virologic Failure Decreases with Duration of HIV Suppression, at Greater than 50% Adherence to Antiretroviral Therapy Rosenblum, Michael Deeks, Steven G. van der Laan, Mark Bangsberg, David R. PLoS One Research Article BACKGROUND: We hypothesized that the percent adherence to antiretroviral therapy necessary to maintain HIV suppression would decrease with longer duration of viral suppression. METHODOLOGY: Eligible participants were identified from the REACH cohort of marginally housed HIV infected adults in San Francisco. Adherence to antiretroviral therapy was measured through pill counts obtained at unannounced visits by research staff to each participant's usual place of residence. Marginal structural models and targeted maximum likelihood estimation methodologies were used to determine the effect of adherence to antiretroviral therapy on the probability of virologic failure during early and late viral suppression. PRINCIPAL FINDINGS: A total of 221 subjects were studied (median age 44.1 years; median CD4+ T cell nadir 206 cells/mm(3)). Most subjects were taking the following types of antiretroviral regimens: non-nucleoside reverse transcriptase inhibitor based (37%), ritonavir boosted protease inhibitor based (28%), or unboosted protease inhibitor based (25%). Comparing the probability of failure just after achieving suppression vs. after 12 consecutive months of suppression, there was a statistically significant decrease in the probability of virologic failure for each range of adherence proportions we considered, as long as adherence was greater than 50%. The estimated risk difference, comparing the probability of virologic failure after 1 month vs. after 12 months of continuous viral suppression was 0.47 (95% CI 0.23–0.63) at 50–74% adherence, 0.29 (CI 0.03–0.50) at 75–89% adherence, and 0.36 (CI 0.23–0.48) at 90–100% adherence. CONCLUSIONS: The risk of virologic failure for adherence greater than 50% declines with longer duration of continuous suppression. While high adherence is required to maximize the probability of durable viral suppression, the range of adherence capable of sustaining viral suppression is wider after prolonged periods of viral suppression. Public Library of Science 2009-09-29 /pmc/articles/PMC2747009/ /pubmed/19787058 http://dx.doi.org/10.1371/journal.pone.0007196 Text en This is an open-access article distributed under the terms of the Creative Commons Public Domain declaration which stipulates that, once placed in the public domain, this work may be freely reproduced, distributed, transmitted, modified, built upon, or otherwise used by anyone for any lawful purpose. https://creativecommons.org/publicdomain/zero/1.0/ This is an open-access article distributed under the terms of the Creative Commons Public Domain declaration, which stipulates that, once placed in the public domain, this work may be freely reproduced, distributed, transmitted, modified, built upon, or otherwise used by anyone for any lawful purpose.
spellingShingle Research Article
Rosenblum, Michael
Deeks, Steven G.
van der Laan, Mark
Bangsberg, David R.
The Risk of Virologic Failure Decreases with Duration of HIV Suppression, at Greater than 50% Adherence to Antiretroviral Therapy
title The Risk of Virologic Failure Decreases with Duration of HIV Suppression, at Greater than 50% Adherence to Antiretroviral Therapy
title_full The Risk of Virologic Failure Decreases with Duration of HIV Suppression, at Greater than 50% Adherence to Antiretroviral Therapy
title_fullStr The Risk of Virologic Failure Decreases with Duration of HIV Suppression, at Greater than 50% Adherence to Antiretroviral Therapy
title_full_unstemmed The Risk of Virologic Failure Decreases with Duration of HIV Suppression, at Greater than 50% Adherence to Antiretroviral Therapy
title_short The Risk of Virologic Failure Decreases with Duration of HIV Suppression, at Greater than 50% Adherence to Antiretroviral Therapy
title_sort risk of virologic failure decreases with duration of hiv suppression, at greater than 50% adherence to antiretroviral therapy
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2747009/
https://www.ncbi.nlm.nih.gov/pubmed/19787058
http://dx.doi.org/10.1371/journal.pone.0007196
work_keys_str_mv AT rosenblummichael theriskofvirologicfailuredecreaseswithdurationofhivsuppressionatgreaterthan50adherencetoantiretroviraltherapy
AT deekssteveng theriskofvirologicfailuredecreaseswithdurationofhivsuppressionatgreaterthan50adherencetoantiretroviraltherapy
AT vanderlaanmark theriskofvirologicfailuredecreaseswithdurationofhivsuppressionatgreaterthan50adherencetoantiretroviraltherapy
AT bangsbergdavidr theriskofvirologicfailuredecreaseswithdurationofhivsuppressionatgreaterthan50adherencetoantiretroviraltherapy
AT rosenblummichael riskofvirologicfailuredecreaseswithdurationofhivsuppressionatgreaterthan50adherencetoantiretroviraltherapy
AT deekssteveng riskofvirologicfailuredecreaseswithdurationofhivsuppressionatgreaterthan50adherencetoantiretroviraltherapy
AT vanderlaanmark riskofvirologicfailuredecreaseswithdurationofhivsuppressionatgreaterthan50adherencetoantiretroviraltherapy
AT bangsbergdavidr riskofvirologicfailuredecreaseswithdurationofhivsuppressionatgreaterthan50adherencetoantiretroviraltherapy